What Does Chugai Still See in a Drug Roche Is Walking Away From?

The most interesting part of the GYM329 announcement is not simply the end of its obesity program. As Roche withdraws from all further development, Chugai is taking back the rights and preparing to resume work in spinal muscular atrophy (SMA)—an indication dropped six months earlier. Licensing the drug to another company is also an option. September 28 announcement ↗

What does Chugai believe is still worth pursuing?

In the SMA trial, strong suppression of mature myostatin in the blood did not translate into consistent gains in muscle mass or motor function. Roche's June conference report also found no clear difference between the low- and high-dose groups. This is not simply a matter of increasing the dose to achieve stronger effects on the target. Roche conference report ↗

That does not mean the entire approach of targeting myostatin has reached a dead end. In a Phase III trial, the competing antibody apitegromab improved motor function in the primary pediatric analysis population: nonambulatory patients with SMA already receiving SMN-targeted treatment. Results were not uniform across individual doses, however, and success with one antibody cannot simply be assumed to apply to another. SAPPHIRE trial publication ↗

There is also a potential difference between the products. Apitegromab was tested as an intravenous infusion every four weeks; GYM329 is given subcutaneously. Chugai itself lists the route of administration among its reasons for reconsidering development. Details of the competing trial ↗

What follows is our interpretation of the business decision.

Rather than suggesting that the drug has suddenly become more promising, the decision may reflect a different view of the product it could become. Even if the plan to add benefits to existing treatments in the large obesity market has fallen through, a drug that benefits a particular group of patients with SMA and offers a different route of administration could justify a different investment decision.

Reclaiming the rights while exploring an outside licensing deal is consistent with that reading. Chugai would not have to carry the program forward alone: it could test the remaining opportunity with a partner bringing different funding or expertise.

But the convenience of a subcutaneous injection cannot make up for inadequate efficacy. Chugai cites long-term data and changes to the trial design, yet it has not explained which patients it now expects to benefit, or what that benefit would look like.

Preparations to restart development should not yet be read as a vindication of the drug's efficacy. The announcement can also be understood as a decision to keep the asset alive—to preserve the option of making it viable under a different product strategy and partnership arrangement.

The substance behind that option should become clearer in the next trial design and any licensing terms. To establish a place for a drug differentiated by subcutaneous administration, which patients will it target, and how much functional improvement will it seek? Once those choices are explicit, the rationale for trying again will be easier to judge.